<DOC>
	<DOCNO>NCT01545141</DOCNO>
	<brief_summary>Determine safety combination IFN , celecoxib , rintatolimod patient recurrent colorectal cancer . This also test whether combination help immune system fight tumor . The result allow investigator determine `` preferred '' combination subsequent extend study .</brief_summary>
	<brief_title>Chemokine-Modulatory Regimen Recurrent Resectable Colorectal Cancer</brief_title>
	<detailed_description>A previously-demonstrated correlation density CRC-infiltrating effector T cell long-term outcome ( Galon et al. , 2006 ; Pages et al. , 2005 ) establish . In preclinical ex vivo study perform use explants resect metastatic CRC , combination IFNα nonselective COX2-selective inhibitor prostaglandin synthesis result elevated production effector T cell-attracting chemokines CXCL10 CCL5 . This associated concomitant suppression intratumoral expression CCL22 , Treg-attracting chemokine ( Muthuswamy et al 2008 Canc Res , Muthuswamy et al , submit Canc Res 2011 ) . However , subset patient , optimal result , particularly regard CCL5 induction , require additional stimulation third agent , poly-I : C ( toll-like receptor -TLR Ligand ) . Therefore , investigator seek establish safety profile novel chemokine regimen consist IFN , celecoxib poly-I : C. The investigator also hypothesize propose neoadjuvant chemokine modulation treatment recurrent CRC patient undergo tumor resection may increase density tumor infiltrate lymphocyte ( TILS ) . In addition , treatment neoadjuvant set allow comparative analysis effect chemokine modulation local recruitment effector-type T cell de-recruitment Treg within resect tumor tissue ; help determine `` preferred '' chemokine-modulating regimen subsequent extend study . Such prospective study focus use combination chemokine modulation cancer vaccine patient CRC . The investigator , example , recently observe αDC1 , new type DC vaccine ( Kalinski Okada , 2010 ; Mailliard et al. , 2004 ) particularly effective induce effector pathway T cell differentiation . This manifested induction tumor-killing function induction effector-type chemokine receptor ( CXCR3 CCR5 ) ( Kalinski Okada , 2010 ; Watchmaker et al. , 2010 ) . Combining αDC1 vaccine safe , tolerable efficacious CKM regimen may hold promise patient poor prognostic CRC .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>poly ( I ) .poly ( c12 , U )</mesh_term>
	<criteria>Inclusion : Recurrent and/or metastatic resectable colorectal cancer , include disease within abdomen pelvis evidence extraabdominal metastasis . Isolated resectable pulmonary metastasis allowable absence intraabdominal metastasis . Intraabdominal disease include : isolate hepatic metastasis/metastases ( see next inclusion criterion point ) , isolated peritoneal metastasis , peritoneal carcinomatosis ( include patient undergo cytoreductive surgery alone combination hyperthermic intraperitoneal chemoperfusion HIPEC ) , combination hepatic extrahepatic metastasis . Patients isolated hepatic metastasis must satisfy Clinical Risk Score 3 high ( see Appendix C ) Eligible patient expect complete resection base preoperative imaging . Any patient find able complete resection eligible study . No chemotherapy , radiotherapy , major surgery , biologic therapy within 3 week protocol treatment An ECOG performance status 0 , 1 , 2 . Age equal 18 year old . Must normal organ marrow function define : Platelet ≥ 75,000/µL Hemoglobin ≥ 9.0 g/dL Hematocrit ≥ 27.0 % Absolute Neutrophil Count ( ANC ) ≥ 1500/µL Creatinine &lt; institutional upper limit normal ( ULN ) OR Creatinine clearance ≥ 50 mL/min/1.73 m2 patient creatinine level great ULN Total bilirubin ≤ 1.5 X institutional upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X institutional upper limit normal ( ULN ) Serum amylase lipase within normal limit . Patient must able understand willing sign write informed consent document . Exclusion : Patients currently treat systemic immunosuppressive agent , include steroid , ineligible 3 week removal immunosuppressive treatment . Patients active autoimmune disease history transplantation . Patients pregnant nursing . Women childbearing potential ( WOCBP ) undergo urine pregnancy test part screen . Patients comorbid medical condition render unfit surgery . Metastatic recurrent disease deem partially resectable unresectable base preoperative imaging . Metastatic disease outside confines abdomen , pelvis thorax ( e.g bone , brain ) Cardiac risk factor include : Patients experience cardiac event ( ) ( acute coronary syndrome , myocardial infarction , ischemia ) within 3 month sign consent Patients New York Heart Association classification III IV ( Appendix A ) History upper gastrointestinal ulceration , upper gastrointestinal bleeding , upper gastrointestinal perforation within past 3 year . Patients ulceration , bleed perforation low bowel exclude . Prior allergic reaction hypersensitivity sulfonamide , celecoxib , NSAIDs . Patients ineligible plan regular use NSAIDs dose 2 time per week ( average ) aspirin 325 mg least three time per week , average . Lowdose aspirin exceed 100 mg/day permit . Patients agree stop regular NSAIDs high dose aspirin eligible wash period require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>recurrent</keyword>
	<keyword>peritoneal metastasis</keyword>
	<keyword>cytoreductive surgery</keyword>
	<keyword>hyperthermic intraperitoneal chemoperfusion</keyword>
	<keyword>HIPEC</keyword>
	<keyword>hepatic metastasis</keyword>
	<keyword>extrahepatic metastasis</keyword>
	<keyword>vaccine</keyword>
</DOC>